Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study

Li,Yan‑Shuang; Yang,Qing; Qi,Ming; Li,Ji‑Yu

doi:10.3892/mco.2017.1351

Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study

Authors:
- Yan‑Shuang Li
- Qing Yang
- Ming Qi
- Ji‑Yu Li
View Affiliations

Affiliations: Department of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: July 28, 2017 https://doi.org/10.3892/mco.2017.1351
Pages: 661-666

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Capecitabine is orally administered and may be safely and conveniently used in patients with cancer. The antitumor activity of capecitabine in breast cancer was mostly demonstrated in the salvage therapy setting, whereas the effect of adjuvant capecitabine monotherapy in breast cancer remains unclear. The aim of the present study was to evaluate adjuvant capecitabine monotherapy in elderly women with breast cancer. A total of 251 patients were enrolled and survival was compared between elderly breast cancer patients who received adjuvant capecitabine monotherapy and those who received no chemotherapy. Cancer‑specific and disease‑free survival curves were compared using log‑rank tests and survival curves were calculated using the Kaplan‑Meier method. Multivariate analyses were conducted using Cox's proportional hazard regression model. There was no significant difference between the clinicopathological characteristics, including age, tumor size, lymph node status, histological grade and hormone status, between patients in the two groups. The breast cancer‑specific survival rate was 89.3% in the capecitabine monotherapy group vs. 81.3% in the no chemotherapy group; the difference was not statistically significant (P=0.128). The disease‑free survival rate was 81.7% in the capecitabine monotherapy group vs. 65.3% in the no chemotherapy group. Kaplan‑Meier analysis indicated a longer disease‑free survival in the capecitabine monotherapy group (P=0.015). On Cox regression analysis, capecitabine monotherapy was found to be associated with the disease‑free survival rate (P=0.014, hazard ratio=0.500) but not with the cancer‑specific survival rate (P=0.181). The adverse events of capecitabine monotherapy were recorded and there was no chemotherapy interruption due to severe adverse reactions. Therefore, adjuvant capecitabine monotherapy in elderly women with breast cancer is a safe and effective option, as well as a viable alternative for elderly breast cancer patients who refuse standard adjuvant therapy.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Joensuu H: Systemic chemotherapy for cancer: From weapon to treatment. Lancet Oncol. 9:3042008. View Article : Google Scholar : PubMed/NCBI
3	Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar
4	Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD and Feuer EJ: Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005. View Article : Google Scholar : PubMed/NCBI
5	Mikhail SE, Sun JF and Marshall JL: Safety of capecitabine: A review. Expert Opin Drug Saf. 9:831–841. 2010. View Article : Google Scholar : PubMed/NCBI
6	Blum JL: The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist. 6:56–64. 2001. View Article : Google Scholar : PubMed/NCBI
7	Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 17:485–493. 1999. View Article : Google Scholar : PubMed/NCBI
8	Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 23:792–799. 2005. View Article : Google Scholar : PubMed/NCBI
9	Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, et al: Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 86:1367–1372. 2002. View Article : Google Scholar : PubMed/NCBI
10	Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL III, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB and Hortobagyi GN: Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist. 17:179–187. 2012. View Article : Google Scholar : PubMed/NCBI
11	Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, et al: Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 29:4498–4504. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kaufmann M, Maass N, Costa SD, Schneeweiss A, Loibl S, Sütterlin MW, Schrader I, Gerber B, Bauer W, Wiest W, et al: First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer. 46:3184–3191. 2010. View Article : Google Scholar : PubMed/NCBI
13	Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU and Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 12:1247–1254. 2001. View Article : Google Scholar : PubMed/NCBI
14	Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, Scotto N and Gralow J: Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 136:777–788. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kamal AH, Camacho F, Anderson R, Wei W, Balkrishnan R and Kimmick G: Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 134:371–378. 2012. View Article : Google Scholar : PubMed/NCBI
16	Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M, Adetiloye AV, Im HK, Akinkuolie AA, Oluwasola A, et al: Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): Efficacy and safety in a phase II feasibility study. Breast J. 19:470–477. 2013.PubMed/NCBI
17	Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP and Krop IE: A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 3:293–299. 2014. View Article : Google Scholar : PubMed/NCBI
18	Li Q, Jiang Y, Wei W, Yang H and Liu J: Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 8:e534032013. View Article : Google Scholar : PubMed/NCBI
19	Jiang Y, Yin W, Zhou L, Yan T, Zhou Q, Du Y, Shen Z, Shao Z and Lu J: First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: A meta-analysis. PLoS One. 7:e324742012. View Article : Google Scholar : PubMed/NCBI
20	Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, et al: Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol. 30:11–18. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hu W, Shi J, Sheng Y, Li L, Su D and Wang CK: Clinical study of adjuvant capecitabine monotherapy in Chinese elderly patients (aged 55–70) with stage IIa breast cancer. Onkologie. 33:433–436. 2010. View Article : Google Scholar : PubMed/NCBI
22	Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 360:2055–2065. 2009. View Article : Google Scholar : PubMed/NCBI
23	Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI
24	Nole F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, Ascione G, Adamoli L, Zampino MG, Minchella I and Goldhirsch A: Capecitabine/vinorelbine: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer. 6:518–524. 2006. View Article : Google Scholar : PubMed/NCBI